Internal Med Medical News about Paclitaxel Lung Neoplasms

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Weekly paclitaxel and cisplatin in the treatment of elderly advanced non-small cell lung cancer
Chinese Journal of Lung Cancer, 10/26/09

LIANG Y et al. – The patients of advanced NSCLC more than 70 years old can tolerate weekly paclitaxel and cisplatin and can get benefit from this regiment.

Methods

50 chemotherapy-naïve patients with advanced NSCLC
> 70 years old
Administrated weekly paclitaxel and pisplatin regiment: PTX 80 mg/m2 intravenous infusion for 1 h, d1, d8 (given routine premedications before PTX), DDP 20 mg/m2 intravenous infusion, d1, d8, every 21 days

Results

50 patients were enrolled, and 48 patients were evaluable for response
ORR (overall response rate) 39.6%
Median survival time (MST) 14.8 months
1 year survival rate 58.3%
Most common adverse events were leucopenia (60%), anemia (62%), nausea and vomiting (30%), alopecia (100%)
No chemotherapy-related deaths